Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700027311

Trial Profile

Clinical Trials Insight: 700027311

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2009

At a glance

  • Drugs Danoprevir; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors InterMune
  • Most Recent Events

    • 24 Apr 2009 Results were presented in an InterMune media release and at the 44th Annual Meeting of the European Association for the Study of the Liver.
    • 12 Jan 2009 Top-line results are reported in an InterMune media release.
    • 12 Jan 2009 Status changed from recruiting to completed, according to a InterMune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top